Biological Polymorphisms of *Helicobacter pylori* on Drug-Susceptibility Test in Clinical Laboratory

**Takeuchi H**, **Oboshi W** and **Nagasawa M**
Department of Medical Laboratory Sciences, Health Sciences, International University of Health and Welfare Graduate School, Japan

*Corresponding author: Takeuchi H, Department of Medical Laboratory Sciences, Health Sciences, International University of Health and Welfare Graduate School, Narita City, Chiba, Japan*

**Received:** September 24, 2018; **Accepted:** October 04, 2018; **Published:** October 11, 2018

**Letter to Editor**

The drug-susceptibility test is necessary and important examination to perform effective antibiotic therapy for individual infectious disorders irrespective to acute and chronic infections. The methodology for drug-susceptibility test in clinical laboratory crucially contributes to select the effective antibiotics in the regimen. Routinely, a strain of the microorganisms causing the infectious disease is subjected to the drug-susceptibility test in clinical laboratory according to application of health issuance and cost-performance. However, the treatment with the antibiotics chose based on the drug-susceptibility test provides not always successful outcome. Concerning with the importance of the problem, we generally accept the bacteria and host-related factors as follows: minor antibiotic resistant which is not detected and poor adherence and individual pharmacokinetics/dynamics in the body.

One of the chronic infectious disorders, the persistent *Helicobacter pylori* infection in the human stomach causes to various manifestations of gastro and extra-gastric disorders as reviewed. *Helicobacter pylori* resistant which is not detected and poor adherence and individual the bacteria and host-related factors as follows; minor antibiotic drug-susceptibility test provides not always successful outcome. Concerning with the importance of the problem, we generally accept the bacteria and host-related factors as follows: minor antibiotic resistant which is not detected and poor adherence and individual pharmacokinetics/dynamics in the body.

The eradication therapy is performed worldwide, however, the eradication failure with antibiotics based on the drug-susceptibility test using a strain is increasing and is worthy of note. Thus, many scientists and medical practitioner are struggling to develop the best regimen for treatment of *H. pylori* infection. They are investigating to figure out more effective combination therapy with antibiotics and gastric acid secretion inhibitors via the randomized clinical trials. Simultaneously the drug-susceptibility test before antimicrobial prescription should be performed with due consideration for the characteristics of the examinations and bacterial features. The difference of drug-susceptibility tests e.g. E-test and agar dilution sometimes differs the values of Minimum Inhibitory Concentration (MIC) [7,8]. Furthermore, in particularly, *H. pylori* utilizes the high proper adaptation strategies mentioned above and survives as *H. pylori* flora in the stomach [4,5], which probably affects the results of the drug-susceptibility test. In the fact, in the case of eradication failure, the discrepancy between the result from the drug-susceptibility test and clinical outcome is reported [6,9-11]. When a single strain is used in the examination, it is hard to provide the accurate result/ MIC value for the effective antibiotic therapy. Thus, we are analyzing with at least each 10 strain from individual patients to clarify the biological polymorphism of *H. pylori* on the drug-susceptibility.

Four antibiotics such as clarithromycin, amoxicillin, metronidazole and sitafloxacin, were used in the drug-susceptibility test. So far, the diversity of MIC value among the multiple strains in the stomach is confirmed by the drug-susceptibility test in clinical laboratory. Interestingly, antibiotic-sensitive and -resistant strains coexisted even in a stomach. Moreover, the MIC values differ among the resistant strains in a stomach. These results seem to relate with the anatomical site where *H. pylori* exists and the history of antibiotic therapy. We need more investigations with the increased cases including primary treatment and eradication failure to clarify the effect of such biological polymorphism of *H. pylori* on the drug-susceptibility.

**References**


**Citation:** Takeuchi H, Oboshi W and Nagasawa M. Biological Polymorphisms of Helicobacter pylori on Drug-Susceptibility Test in Clinical Laboratory. J Bacteriol Mycol. 2018; 5(6): 1081.